Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using rationally defined bacterial consortia manufactured from clonal cell banks, today announced that members of its management team will participate in the SVB Leerink Biopharma Private Company Connect Event being held virtually Thursday, May 6 - Friday, May 7, 2021.
Event: SVB Leerink Biopharma Private Company Connect Event
Date: Thursday, May 6 - Friday, May 7, 2021
About Vedanta Biosciences
Vedanta Biosciences is leading the development of a potential new category of oral therapies for immune-mediated diseases using rationally defined bacterial consortia manufactured from clonal cell banks. The Company’s approach bypasses the need to rely on direct sourcing of donor fecal material of inconsistent composition, thus overcoming challenges related to safety, quality, and scalability that limit donor-derived approaches. The clinical pipeline includes product candidates being evaluated for the treatment of C. difficile infection, inflammatory bowel diseases, advanced or metastatic cancers, and food allergy. These investigational therapies are grounded in pioneering research – published in leading journals including Science, Nature, and Cell – that identified bacteria that induce a range of beneficial immune responses. The Company’s platform includes what is believed to be the largest library of bacteria derived from the human microbiome, high throughput methods for bacterial consortium design, vast datasets from human interventional studies, and state-of-the-art capabilities for cGMP-compliant manufacturing of defined bacterial consortia. Vedanta Biosciences controls a foundational intellectual property portfolio covering compositions of matter and methods of use for classes of bacteria that play key roles in human health. Vedanta Biosciences was founded by PureTech Health (Nasdaq: PRTC, LSE: PRTC) and a global team of scientific co-founders who pioneered the modern understanding of how the immune system and the microbiome cross-talk.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210429005325/en/
Contacts
Investors and Media
Chris Brinzey
+1 617 835 9304
Chris.Brinzey@westwicke.com
